TSE:RVX Resverlogix (RVX) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free RVX Stock Alerts C$0.05 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's RangeC$0.05▼C$0.0550-Day RangeC$0.05▼C$0.0752-Week RangeC$0.05▼C$0.12Volume3,000 shsAverage Volume37,306 shsMarket CapitalizationC$13.74 millionP/E RatioN/ADividend Yield7.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Resverlogix alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Resverlogix Stock (TSE:RVX)Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.Read More RVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVX Stock News HeadlinesMay 28, 2024 | finance.yahoo.comResverlogix Announces Updated Annual and Special Meeting of ShareholdersMay 16, 2024 | finance.yahoo.comResverlogix Corp. (RVX.TO)May 13, 2024 | finance.yahoo.comResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion PrivilegesFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsJanuary 11, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsJanuary 4, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)December 19, 2023 | investing.comResverlogix Corp. (RVX) Earnings Dates & ReportsNovember 18, 2023 | morningstar.comResverlogix Corp RVXCFNovember 1, 2023 | morningstar.comResverlogix Corp RVXOctober 18, 2023 | theglobeandmail.comResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)October 4, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finance.yahoo.comResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophySeptember 26, 2023 | finance.yahoo.comAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAugust 29, 2023 | finance.yahoo.comResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesAugust 24, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp up on Wednesday (RVX)August 14, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Monday (RVX)July 12, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)June 29, 2023 | finance.yahoo.comResverlogix Announces Warrant Repricing and One-Year ExtensionJune 20, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 20, 2023 | finance.yahoo.comResverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 12, 2023 | finance.yahoo.comResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease PatientsJune 7, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - RVX.WT.AJune 6, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)May 25, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)May 18, 2023 | finance.yahoo.comCBOE RUSSELL 2000 VOLATILITY IN (^RVX)See More Headlines Receive RVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today6/15/2024Next Earnings (Estimated)8/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:RVX CUSIPN/A CIKN/A Webwww.resverlogix.com Phone+1-403-2549252FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-16,740,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-44.23% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow132.50 Book ValueC($0.27) per share Price / Book-0.19Miscellaneous Outstanding Shares274,820,000Free FloatN/AMarket CapC$13.74 million OptionableNot Optionable Beta0.69 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & SecretaryMr. Aaron Bradley Cann C.A.CPA, CBV, Chief Financial OfficerDr. Ewelina Kulikowski Ph.D.Chief Scientific OfficerDr. Michael Sweeney M.D. (Age 63)Senior Vice President of Clinical Development Comp: $511.56kSarah ZapotichnyDirector of Investor Relations & Corporate CommunicationsKey CompetitorsEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTCovalon TechnologiesCVE:COVMicrobix BiosystemsTSE:MBXView All Competitors RVX Stock Analysis - Frequently Asked Questions How have RVX shares performed in 2024? Resverlogix's stock was trading at C$0.07 on January 1st, 2024. Since then, RVX stock has decreased by 28.6% and is now trading at C$0.05. View the best growth stocks for 2024 here. When is Resverlogix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our RVX earnings forecast. How were Resverlogix's earnings last quarter? Resverlogix Corp. (TSE:RVX) announced its quarterly earnings data on Monday, April, 1st. The biotechnology company reported ($0.01) EPS for the quarter. What other stocks do shareholders of Resverlogix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Endocyte (ECYT), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX) and Royalty Pharma (RPRX). How do I buy shares of Resverlogix? Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:RVX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.